Goldman Sachs
RANI icon

Goldman Sachs’s Rani Therapeutics RANI Stock Holding History

Goldman Sachs’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.69K Sell
11,826
-274,006
-96% -$350K ﹤0.01% 6385
2025
Q4 		$386K Buy
+285,832
New +$431K ﹤0.01% 5754
2023
Q2 		– Sell
-33,532
Closed -$173K – 6010
2023
Q1 		$173K Buy
+33,532
New +$202K ﹤0.01% 5343
2022
Q3 		– Sell
-10,739
Closed -$111K – 6490
2022
Q2 		$111K Sell
10,739
-16,081
-60% -$185K ﹤0.01% 5824
2022
Q1 		$362K Buy
+26,820
New +$445K ﹤0.01% 5541
2021
Q4 		– Sell
-60,649
Closed -$1.08M – 6662
2021
Q3 		$1.08M Buy
+60,649
New +$1.05M ﹤0.01% 4683

Other funds holding RANI

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
LP
Longaeva Partners Chicago, Illinois $2.7B AUM 37.16% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Goldman Sachs's RANI Position: Q1 2026 in Review

Goldman Sachs reduced its Rani Therapeutics (RANI) stake by 96% in Q1 2026, selling an estimated $350K and leaving 11,826 shares worth $8.69K. The position accounts for ﹤0.01% of the portfolio, ranked #6385.

Goldman Sachs first reported a position in RANI in Q3 2021 and has held it in 6 quarters since. The position peaked at $1.08M in Q3 2021. 74 funds tracked by Wall St. Rank hold RANI as of Q1 2026.

  • Goldman Sachs held 11,826 shares of Rani Therapeutics worth $8.69K as of Q1 2026.
  • Goldman Sachs sold 274,006 Rani Therapeutics shares in Q1 2026, an estimated $350K.
  • Rani Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6385 holding.
  • Goldman Sachs first reported a position in Rani Therapeutics in Q3 2021 and has held it in 6 quarters since.
  • Goldman Sachs's Rani Therapeutics position peaked at $1.08M in Q3 2021.
  • 74 funds tracked by Wall St. Rank held Rani Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.